| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 581.68 | 0.8% | 13.4% |
| Total Income | 582.19 | 0.9% | 13.4% |
| Expenditure | 540.09 | 0.3% | 14.6% |
| PBT | 42.10 | 14.4% | 0.1% |
| Net Profit | 32.77 | 11.1% | 3.4% |
| OPM | 11.84% | 0.43pp | 8.28pp |
| NPM | 5.63% | 0.64pp | 0.48pp |
| EPS | 5.92 | 11.1% | 3.3% |
Rossari Biotech Announces Q3 FY26 Results: Revenues Up 13%, EBITDA Up 6%, PAT Up 3%
19 Jan 2026 · 19 Jan, 11:50 am
Summary
Rossari Biotech Limited, a Specialty-Chemicals manufacturer, has announced its financial results for the quarter ended December 31, 2025. The company reported a 13% YoY growth in revenue, 6% YoY growth in EBITDA, and 3% YoY growth in PAT.
Key Highlights
- 1
Q3 FY26 Revenues at Rs. 581.7 Cr, up 13% YoY
- 2
EBITDA at Rs. 68.9 Cr, up 6% YoY
- 3
PAT at Rs. 32.8 Cr, up 3% YoY
- 4
HPPC recorded a YoY growth of 11%
- 5
TSC delivered a growth of 18% YoY
- 6
AHN grew by 39% YoY
- 7
Board grants in-principle approval to set up greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia
Management Comments
Mr. Edward Menezes
Promoter & Executive Chairman
We delivered healthy YoY growth in Q3 FY26 despite a softer domestic demand environment during the quarter. Consolidated revenues grew by 13% YoY, supported by a balanced contribution across business segments and continued traction in our international operations.
Mr. Sunil Chari
Promoter & Managing Director
Profitability was impacted by ongoing investments in capacity expansion, product development and market-seeding initiatives. These investments are intended to strengthen our long-term competitive positioning, and we remain confident that operating leverage, scale benefits and an improving product mix will support margin improvement over time.
Informational and educational content only. Not investment advice.